HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Peng, J. Articles by Xu, Y. Search for Related Content PubMed PubMed Citation Articles by Peng, J. Articles by Xu, Y. Agricola Articles by Peng, J. Articles by Xu, Y.

Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties

¹ School of Life Sciences and Technology, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, PR China
² School of Pharmacy, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, PR China
³ Shanghai GenePharma Co. Ltd, 501 Newton Road, Shanghai, PR China

Correspondence
Yuhong Xu
yhxu{at}sjtu.edu.cn

The strategy of RNA interference (RNAi)-based gene silencing has been suggested to have great potential in treating viral diseases. It provides new hope of being able to complement the limited therapeutic options currently available for chronic hepatitis B virus (HBV) infection. To advance such a strategy towards clinical use, the effects of various parameters on the anti-HBV efficiency of RNAi need to be well-defined. In this study, the efficacy and pharmacodynamic properties of different RNAi target sequences and constructs were examined. Several sequences were found to be effective in cell and animal models, achieving inhibition rates of approximately 80–90 %. Methyl-modified small interfering RNA (siRNA) molecules were found to be more stable inside cells than natural siRNA molecules and offered longer-lasting inhibitory effects. Both were effective at rather low doses (an equimolar ratio with HBV preS2–S protein expression vector). Plasmid DNA vectors were less dose-responsive, but their effectiveness in vivo lasted longer, for approximately 1 month. By analysing these different parameters and their possible mechanisms, some important issues in RNAi therapeutics that should assist the future development of clinical applications have been addressed.

This article has been cited by other articles:

				A. C. W. Jenke, A. D. Wilhelm, V. Orth, H. J. Lipps, U. Protzer, and S. Wirth Long-Term Suppression of Hepatitis B Virus Replication by Short Hairpin RNA Expression Using the Scaffold/Matrix Attachment Region-Based Replicating Vector System pEPI-1 Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2355 - 2359. [Abstract] [Full Text] [PDF]